Shengling Fu1,2, Jiayuh Lin3. 1. Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China. 2. Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD, U.S.A. 3. Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD, U.S.A. JLin@som.umaryland.edu.
Abstract
BACKGROUND/AIM: Interleukin-6 (IL-6) and interleukin-8 (IL-8) play important roles in the progression of triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). This is the first experiment to combine small molecules targeting these two signaling pathways to treat TNBC and PDAC cells. MATERIALS AND METHODS: Cell viability, colony formation and cell migration assays were conducted when TNBC or PDAC cells were treated with bazedoxifene (targeting IL-6) or reparixin/SCH527123 (targeting IL-8) or their combination. RESULTS: The combined treatment had a more potent inhibition of cell viability, colony formation and cell migration than monotherapy in TNBC and PDAC cells. The results also showed that the combination of bazedoxifene with SCH527123 seemed to be more effective than that with reparixin in inhibiting cell viability and colony formation of TNBC. CONCLUSION: Novel drug combinations of bazedoxifene and reparixin, as well as bazedoxifene and SCH527123 may provide more effective treatments for TNBC and PDAC. Copyright
BACKGROUND/AIM: Interleukin-6 (IL-6) and interleukin-8 (IL-8) play important roles in the progression of triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC). This is the first experiment to combine small molecules targeting these two signaling pathways to treat TNBC and PDAC cells. MATERIALS AND METHODS: Cell viability, colony formation and cell migration assays were conducted when TNBC or PDAC cells were treated with bazedoxifene (targeting IL-6) or reparixin/SCH527123 (targeting IL-8) or their combination. RESULTS: The combined treatment had a more potent inhibition of cell viability, colony formation and cell migration than monotherapy in TNBC and PDAC cells. The results also showed that the combination of bazedoxifene with SCH527123 seemed to be more effective than that with reparixin in inhibiting cell viability and colony formation of TNBC. CONCLUSION: Novel drug combinations of bazedoxifene and reparixin, as well as bazedoxifene and SCH527123 may provide more effective treatments for TNBC and PDAC. Copyright
Authors: Leah H Ackerman; Carlos H de Mello Souza; Galaxia Cortés-Hinojosa; Marc E Salute; Alexa A Stephen; Elizabeth Anthony; Keijiro Shiomitsu; Rowan J Milner Journal: Can J Vet Res Date: 2022-01 Impact factor: 0.897
Authors: Miles E Cameron; Patrick W Underwood; Iverson E Williams; Thomas J George; Sarah M Judge; Joshua F Yarrow; Jose G Trevino; Andrew R Judge Journal: Cancer Med Date: 2021-11-17 Impact factor: 4.452
Authors: Sarah Peisl; Claudia Mellenthin; Lucie Vignot; Carmen Gonelle-Gispert; Leo Bühler; Bernhard Egger Journal: PLoS One Date: 2021-06-17 Impact factor: 3.240
Authors: Julia López de Andrés; Carmen Griñán-Lisón; Gema Jiménez; Juan Antonio Marchal Journal: J Hematol Oncol Date: 2020-10-15 Impact factor: 17.388